Syndax PharmaceuticalsFRA:1T3 -0.47%25 Quick Ratio is 5.06 as of Mar. 2026, which is 43% below its 10-year median of 8.88. GuruFocus rates FRA:1T3 with a GF Score™ of 25/100. The stock has 7 warning signs investors should review. Among 1,412 Biotechnology companies, Syndax Pharmaceuticals ranks better than 60.41% on this metric.
Syndax Pharmaceuticals has a quick ratio of 5.06. It generally indicates good short-term financial strength.
The historical rank and industry rank for Syndax Pharmaceuticals's Quick Ratio or its related term are showing as below:
FRA:1T3'
s Quick Ratio Range Over the Past 10 Years
Min: 3.39 Med: 8.88 Max: 21.68
Current: 5.06
During the past 13 years, Syndax Pharmaceuticals's highest Quick Ratio was 21.68. The lowest was 3.39. And the median was 8.88.
FRA:1T3's Quick Ratio is ranked better than 60.41% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:1T3: 5.06
Syndax Pharmaceuticals (FRA:1T3) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Syndax Pharmaceuticals Quick Ratio Related Terms
Syndax Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1T3 vs IOVA, GLUE, TYRA: Quick Ratio Comparison
For the Biotechnology subindustry, Syndax Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syndax Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Syndax Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Syndax Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syndax Pharmaceuticals (FRA:1T3) has a Quick Ratio of 5.06 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Syndax Pharmaceuticals and its competitors. This is 43% below median its historical median of 8.88. Over the past decade, Syndax Pharmaceuticals' Quick Ratio has ranged from 3.39 to 21.68. According to the industry distribution chart, Syndax Pharmaceuticals ranks #559 out of 1412 companies in the Biotechnology industry, placing it in the top 39.6%.
Is Syndax Pharmaceuticals' Quick Ratio too high?
Syndax Pharmaceuticals' current Quick Ratio of 5.06 is 43% below median its 10-year median of 8.88. Over the past 10 years, this metric has ranged from a low of 3.39 to a high of 21.68. The Biotechnology industry median Quick Ratio is 3.60. Syndax Pharmaceuticals' value of 5.06 is 40.6% above this industry median. Based on the distribution chart, Syndax Pharmaceuticals ranks #559 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Syndax Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Quick Ratio compare to IOVA and GLUE?
According to the Biotechnology industry distribution chart, Syndax Pharmaceuticals ranks #559 out of 1412 companies for Quick Ratio. This puts Syndax Pharmaceuticals in the upper half of its industry. The industry median Quick Ratio is 3.60. Syndax Pharmaceuticals' value of 5.06 is 40.6% above this benchmark. Historically, Syndax Pharmaceuticals' own Quick Ratio has ranged from 3.39 to 21.68 over the past decade. While the company's 10-year median is 8.88 vs. the industry median of 3.60, Syndax Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syndax Pharmaceuticals's current Quick Ratio of 5.06 is 40.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Syndax Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syndax Pharmaceuticals's current Quick Ratio is 5.06, which is 43% below median its own 10-year median of 8.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current Quick Ratio of 5.06. The current Quick Ratio is 5.06, which is 43% below median its 10-year median of 8.88 and 40.6% above the Biotechnology industry median of 3.60. Syndax Pharmaceuticals' overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current Quick Ratio is 5.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
25GF Score
Get the complete analysis for FRA:1T3
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1T3 has been successfully added to your 
